Journal of Bone and Joint Infection · Published 2026-01-13 · DOI 10.5194/jbji-11-31-2026
<p><strong>Introduction</strong>: Fungal periprosthetic joint infection (PJI) has historically been reported in 1 %–2 % of cases, with <i>Candida</i> species accounting for most isolates. However, the true incidence is likely underestimated. Standard aerobic and anaerobic culture techniques have limited sensitivity for detecting fungi, single positive fungal cultures are often excluded or inconsistently classified, culture-negative infections may mask low-burden fungal pathogens, and polymicrobial cultures may obscure the contribution of fungal organisms. The objective of this study was to quantify the burden of potentially unrecognized fungal involvement and provide a more accurate estimate of the incidence of <i>Candida</i>-associated PJI. <strong>Methods</strong>: Following a systematic literature search, we performed a quantitative sensitivity analysis using imputation with informative missingness odds ratios (IMORs). Reported <i>Candida</i> cases were adjusted for four predefined sources of under-ascertainment: single positive cultures, negative cultures, polymicrobial cultures, and variability in fungal culture sensitivity. <strong>Results</strong>: 23 studies met inclusion criteria, reporting a total of 28 253 PJI patients, of whom 590 had <i>Candida</i> involvement (2.1 %; range 0.9 %–10.1 %). After imputation for missing data, the estimated proportion of PJI cases involving <i>Candida</i> ranged from 1.4 %–13.6 %, with a mean of 5.1 %. The odds ratios for known risk factors for chronic refractory PJI exceeded 2.0, suggesting the proportion of <i>Candida</i> in this population likely exceeds 10 %. <strong>Conclusion</strong>: The involvement of <i>Candida</i> in PJI is likely underreported. The adjusted incidence is approximately 5 % across all PJI cases. Among patients with chronic refractory PJI, especially those that have failed multiple surgeries, the incidence of <i>Candida</i> PJI is approximately 10 %. <strong>Level of Evidence</strong>: Level III.</p>
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →